The Original Investigation titled “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018,” published in the March 3, 2020, issue of JAMA,1 was corrected to update data throughout the article. The data changes originated because of corrections to one of the studies used as a source for clinical trial success rates. In addition to updated data throughout the Original Investigation, accompanying Editorials and Letters necessitated corrections to data.2,3,4,5,6 These articles have been corrected online, and a letter of explanation appears in this issue.7
References
- 1.Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-853. doi: 10.1001/jama.2020.1166 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Deb C, Curfman G. Relentless prescription drug price increases. JAMA. 2020;323(9):826-828. doi: 10.1001/jama.2020.0359 [DOI] [PubMed] [Google Scholar]
- 3.Cutler DM. Are pharmaceutical companies earning too much? JAMA. 2020;323(9):829-830. doi: 10.1001/jama.2020.0351 [DOI] [PubMed] [Google Scholar]
- 4.Dierynck B, Joos P. Research and development costs of new drugs. JAMA. 2020;324(5):516-517. doi: 10.1001/jama.2020.8642 [DOI] [PubMed] [Google Scholar]
- 5.DiMasi JA. Research and development costs of new drugs. JAMA. 2020;324(5):517. doi: 10.1001/jama.2020.8648 [DOI] [PubMed] [Google Scholar]
- 6.Wouters OJ, McKee M, Luyten J. Research and development costs of new drugs—reply. JAMA. 2020;324(5):518. doi: 10.1001/jama.2020.8651 [DOI] [PubMed] [Google Scholar]
- 7.Wouters OJ, McKee M, Luyten J. Errors in source data for study of drug development costs. JAMA. Published September 20, 2022. doi: 10.1001/jama.2022.14317 [DOI] [PubMed] [Google Scholar]
